20-valent pneumococcal polysaccharide conjugate vaccine clinical research application accepted
February 1, 2025
Source: drugdu
98
Watson Bio (300142) announced on the evening of January 21 that the 20-valent pneumococcal polysaccharide conjugate vaccine jointly developed by the company and its subsidiaries Yuxi Watson Biotechnology Co., Ltd. and Yunnan Vaccine Laboratory Co., Ltd. applied to the National Medical Products Administration for clinical trials and recently obtained the "Acceptance Notice". The 20-valent pneumococcal polysaccharide conjugate vaccine (PCV20) is independently developed by the company. It is an upgraded product developed on the basis of the company's 13-valent pneumococcal polysaccharide conjugate vaccine that has been produced and marketed, covering more pneumococcal pathogenic serotypes. In addition, the company decided to terminate the clinical research related work of the DTaP-Hib quadruple vaccine.
https://finance.eastmoney.com/a/202501213303737886.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Will not transfer main business or inject assets to Tiankang Pharmaceutical March 10, 2025
- The first tumor vaccine is expected to be launched in 2027 to treat this cancer March 10, 2025
- Another pharmaceutical company changes ownership March 10, 2025
- Sinclair Xinkeli Aesthetic Medical Multifunctional Operation Platform V30 Registration Application Accepted March 10, 2025
- Focusing on critical illness, Mindray Biotech and Likang Biomedical have reached a strategic cooperation March 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
